Skip to main content

Stemtech Cororation Announces Life Factor Research Obtains First Production Contract With New Customer

MIRAMAR, FL / ACCESSWIRE / December 22, 2022 / Stemtech Corporation (OTCQB:STEK) today announced that Life Factor Research, the Research and Development Division of Stemtech, has acquired its first contract to produce a while label product for a new client.

Stemtech President & COO, John W. Meyer, announced that "under Life Factor Research, a division of Stemtech, a new customer was acquired to produce a custom, white-labeled product to be sold through their new customer's distribution channel."

Life Factor Research CEO, Charles Layton, says "we are very pleased to be able to announce the addition of a new and very substantive client who will be bringing a very needed OTC Flu and Cold product to the market in the first quarter of 2023. This will be the first of many clinically and scientifically proven formulations that have been agreed upon to be introduced under this new brand. The initial offering is a registered Pharmacopeia Formulation with virtually decades of proven efficacy in lessening the effects of air borne viruses when taken at the outset of symptoms as directed. LFR will be taking the proven active compound and mechanism of action and converting it into a much more consumer friendly, good tasting and fast acting dissolvable lozenge."

"Our new client not only has a large vision for market penetration in this needed category, but with their "in-house" ecommerce expertise and LFR's established distribution channels there is growing excitement for this new brand to rise in the ranks of consumer confidence and participation."


Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and has expanded business opportunities for its Independent Business Partners, who may earn incomes by sharing Stemtech products. January 2022 saw the introduction of new marketing efforts. In August 2022, Professor Doctor Bankole Johnson joined Dr. Enrique Martinez and Dr. Lizette Leos on the Stemtech Life Sciences Advisory Board. In September 2022, the new Stemtech AdvanceOffice mobile app based on the VERB Technology platform was successfully launched as a powerful communication - recruiting tool for our Field. In October, Life Factor Research became the Research and Development, product formulation - science division of Stemtech to create cutting-edge stemceuticals and other products. On November 1, 2022, Stemtech introduced the new travel/sample size OraStem® Toothpaste. On December 6, Stemtech announced the promotion of Alejandro Carrillo to the role of Vice President Global Sales from his current role as Managing Director Latin Markets. Stemtech introduced the new CellectOne™ Rapid Renew Stem Cell Peptide Night Moisturizer at their December International Leadership Event in Cancun, Mexico.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on November 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Investor Relations:

Phone: 954-715-6000 ext 1040

SOURCE: Stemtech Corporation

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.